Evidence map›Paper›PMID 25060773›Full record

ReviewThe AAPS journal2014

Next generation ligand binding assays-review of emerging real-time measurement technologies.

Stephanie Fraser, Mark Cameron, Edward O'Connor, Martin Schwickart, Michael Tanen, Mark Ware

Abstract readReview
In one paragraph

Review in The AAPS journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Profiling inflammation and tissue injury markers in perfusate and bronchoalveolar lavage fluid during human ex vivo lung perfusion.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2017
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephanie FraserPfizer Global Research and Development, Groton, Connecticut, USA, stephanie.fraser@pfizer.com.
Mark Cameron
Edward O'Connor
Martin Schwickart
Michael Tanen
Mark Ware

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last few years, numerous ligand binding assay technologies that utilize real-time measurement have been introduced; however, an assemblage and evaluation of these technologies has not previously been published. Herein, we describe six emerging real-time measurement technologies: Maverick™, MX96 SPR™, NanoDLSay™, AMMP®/ViBE®, SoPrano™, and two Lab-on-a-Chip (LoC) microfluidic devices. The development stage gate of these technologies ranges from pre-commercial to commercially available. Due to the novelty, the application and utility of some of the technologies regarding bioanalysis are likely to evolve but it is our hope that this review will provide insight into the direction the development of real-time measurement technologies is moving and the vision of those that are taking us there. Following the technology discussions, a comprehensive summary table is presented.

Indexed as

Drug DesignLigandsAcousticsAnimalsBinding SitesEquipment DesignHumansKineticsMicrofluidic Analytical TechniquesMiniaturizationNanotechnologyPharmaceutical PreparationsProtein BindingSurface Plasmon ResonanceTechnology, PharmaceuticalLigandsPharmaceutical Preparations

Identifiers

PMID25060773
PMCPMC4147046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.